Completion of acquisition of Systagenix

Acquisition of share capital of Systagenix completed 1 October 2018

2 October 2018

LEI No. 213800QIPVTK5ES5UU36 

Scapa Group Ltd (“Scapa” or “the Group”)

Completion of Acquisition of Systagenix Advanced Wound Dressing Facility in Gargrave
Entering a 5-year exclusive manufacturing and supply agreement

Further to the announcement made on 13 September 2018, Scapa Group Ltd (AIM: SCPA) is pleased to announce that its acquisition of the share capital of Systagenix Wound Management Manufacturing Limited completed on 1 October 2018.  In addition, Scapa and Acelity have now entered into the exclusive five-year manufacturing and supply agreement for Systagenix advanced wound care products that are currently manufactured in the Gargrave facility, with immediate effect.

For further information:
Scapa Group Ltd
Heejae Chae – Group Chief Executive
Oskar Zahn – Chief Financial Officer   
0161 301 7430

Numis Securities Limited
(Nominated Adviser and Joint Broker)
Richard Thomas/Mark Lander 
020 7260 1000 

(Joint Broker)
Chris Bowman 
020 3207 7800

Weber Shandwick Financial PR
Nick Oborne   
020 7067 0000